- Conditions
- Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
- Interventions
- Rucaparib, Lucitanib, Sacituzumab govitecan
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 10,858
matching trials from the live ClinicalTrials.gov search.
- Conditions
- B-cell Chronic Lymphocytic Leukemia
- Interventions
- Lenalidomide, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Fountain Valley, California • San Diego, California + 48 more
- Conditions
- Infertility Primary
- Interventions
- Magenta AI image analysis tool
- Other
- Lead sponsor
- Ovation Fertility
- Other
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Las Vegas, Nevada • Cincinnati, Ohio • Nashville, Tennessee
- Conditions
- Clostridium Difficile
- Interventions
- Misoprostol 100Mcg Tab, Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia
- Interventions
- romidepsin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Nashville, Tennessee
- Conditions
- Lower Urinary Tract Symptoms, Overactive Bladder
- Interventions
- Urodynamics + TETRA - NIRS
- Device
- Lead sponsor
- Laborie Medical Technologies Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Neoplasms
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 5 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, rebimastat
- Drug
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 774 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 12 more
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
- Interventions
- EYE201
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Talquetamab, Teclistamab, Pomalidomide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- Duarte, California • Irvine, California • San Francisco, California + 6 more
- Conditions
- Hyperhidrosis
- Interventions
- Vehicle, ANT-1207
- Biological
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 19
- States / cities
- Hialeah, Florida • Miami, Florida • Pinellas Park, Florida + 16 more
- Conditions
- GERD
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Liver Fibrosis Due to NASH
- Interventions
- Placebo, SIM
- Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Coronado, California • San Diego, California + 35 more
- Conditions
- Cannabis Use, SCHIZOPHRENIA, Psychosis, rTMS
- Interventions
- 3 Minute iTBS to the L DLPFC, One-Minute, Personalized, DMN Targeted CTBS
- Device
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- GB0139, Placebo
- Drug
- Lead sponsor
- Galecto Biotech AB
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 34
- States / cities
- Andalusia, Alabama • Jasper, Alabama • Palm Springs, California + 29 more
- Conditions
- End-Stage Renal Disease
- Interventions
- Anakinra, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Huntington Disease
- Interventions
- RO7234292 (RG6042)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • La Jolla, California • Palo Alto, California + 11 more
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- IW-3718, placebo, Standard-dose PPIs QD
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Peoria, Arizona + 81 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Osimertinib, Lazertinib, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,074 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 20
- States / cities
- Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more
- Conditions
- Depression
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diabetes Mellitus
- Interventions
- Diabetes Care Gaps Patient Portal Intervention
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Macular Edema, Branch Retinal Vein Occlusion
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
- Conditions
- Tourette Syndrome
- Interventions
- TEV-50717, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 19
- States / cities
- Gainesville, Florida • Gulf Breeze, Florida • Miami, Florida + 14 more
- Conditions
- Weight Gain, Autism Spectrum Disorder, Medication Side Effect
- Interventions
- Comparison of Risperidone and Aripiprazole
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee